Want to see AZR full AI Analyst Report?
Azora Therapeutics (AZR) AI Stock Analysis
Azora Therapeutics
(NASDAQ:AZR)
The score is primarily weighed down by weak financial performance (pre-revenue, widening losses, ongoing cash burn, and negative equity). Technicals are also soft with the stock trading below key short-to-mid moving averages and slightly negative MACD. Corporate events add meaningful uncertainty due to Nasdaq compliance risk, while valuation provides limited support given negative earnings and no dividend.
Azora Therapeutics (AZR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $13.26M
- Dividend Yield
- ―
- Average Volume (3M)
- 58.76K
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 1.44
- Revenue Growth
- ―
- EPS Growth
- 45.78%
- Country
- US
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Azora Therapeutics Business Overview & Revenue Model
Company Description
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Adial has historically not generated meaningful recurring revenue from commercial product sales because its primary drug candidate(s) have been in development rather than approved and marketed. Its abili...
Azora Therapeutics Financial Statement Overview
Summary
Financials reflect a high-burn, pre-revenue biotech: no reported revenue, sharply wider TTM net loss (~$57.8M), and persistent negative operating/free cash flow (~-$11.1M). While debt is minimal, stockholders’ equity turning deeply negative (~-$38.4M) materially increases financial fragility.
Income Statement
8Very NegativeBalance Sheet
12Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -141 | 0 | 0 | -564 | 0 | 0 |
| EBITDA | -57.80M | -7.98M | -13.20M | -7.00M | -10.80M | -17.69M |
| Net Income | -57.80M | -7.98M | -13.20M | -7.00M | -12.73M | -19.42M |
Balance Sheet | ||||||
| Total Assets | 29.09M | 6.80M | 5.04M | 4.74M | 5.73M | 7.63M |
| Cash, Cash Equivalents and Short-Term Investments | 28.71M | 5.88M | 3.75M | 2.83M | 4.00M | 6.06M |
| Total Debt | 0 | 0 | 0 | 0 | 207.38K | 256.96K |
| Total Liabilities | 28.93M | 1.52M | 975.86K | 653.51K | 2.46M | 4.13M |
| Stockholders Equity | 156.00K | 5.28M | 4.07M | 4.08M | 3.28M | 3.51M |
Cash Flow | ||||||
| Free Cash Flow | -11.13M | -6.49M | -6.92M | 0 | -11.19M | -12.01M |
| Operating Cash Flow | -11.13M | -6.49M | -6.92M | -6.81M | -11.19M | -11.95M |
| Investing Cash Flow | 5.28M | 150.00K | 0 | 1.50M | 0 | -34.02K |
| Financing Cash Flow | 28.65M | 8.47M | 7.85M | 4.13M | 9.13M | 13.64M |
Azora Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZR, the sentiment is Negative. The current price of 3.81 is below the 20-day moving average (MA) of 3.87, below the 50-day MA of 4.69, and above the 200-day MA of 3.22, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 46.48 is Neutral, neither overbought nor oversold. The STOCH value of 72.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZR.
Azora Therapeutics Risk Analysis
Azora Therapeutics disclosed 80 risk factors in its most recent earnings report. Azora Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAzora Therapeutics Peers Comparison
Overall Rating
KPRX43Neutral- AZR42Neutral
CLDI41Neutral
MTNB37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| KPRX | 43Neutral | $6.90M | -0.62 | -63.39% | ― | ― | 19.38% |
| AZR | 42Neutral | $10.00M | -0.30 | -1693.21% | ― | ― | 45.78% |
| CLDI | 41Neutral | $2.53M | -0.01 | -372.86% | ― | ― | 53.95% |
| MTNB | 37Underperform | $1.48M | -0.08 | -181.45% | ― | ― | 68.91% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AZR | Azora Therapeutics, Inc. | 3.81 | -4.81 | -55.83% | |
| KPRX | Kiora Pharmaceuticals, Inc. | 1.56 | -0.91 | -36.84% | |
| MTNB | Matinas BioPharma Holdings | 1.51 | -18.59 | -92.49% | |
| ALZN | Alzamend Neuro, Inc. | 1.21 | -1.33 | -52.36% | |
| CLDI | Calidi Biotherapeutics, Inc. | 0.69 | -23.79 | -97.19% |
Azora Therapeutics Corporate Events
Azora Therapeutics Rebrands and Installs New Leadership Team
PositiveOn October 28, 2026, Azora Therapeutics, Inc., formerly Adial Pharmaceuticals, implemented a sweeping corporate repositioning that included a name change, a new Nasdaq ticker “AZR,” and an expansion of authorized common shares from 100 mi...
Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing
NeutralAdial Pharmaceuticals convened its 2026 Annual Meeting of Stockholders on September 17, 2026, but proceeded only with votes on certain proposals while adjourning votes on Proposals 3, 4, 5 and 6 to allow time to obtain Nasdaq’s conditional appr...
Adial Pharmaceuticals Adjourns Meeting Pending Nasdaq Listing Decision
NegativeAdial Pharmaceuticals reconvened its 2026 Annual Meeting of Stockholders on October 1, 2026 to address Proposals 3, 4, 5 and 6 but again postponed the vote because it had not yet received Nasdaq’s approval of its listing application. The meetin...
Adial Shareholders Approve Key Proposals, Meeting Adjourned
NeutralOn September 17, 2026, Adial Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where a quorum representing 48.7% of outstanding common shares participated. Shareholders elected two Class II directors, ratified CBIZ CPAs P.C. as the...
Adial Pharmaceuticals Amends Agreements to Restore Nasdaq Compliance
NeutralAdial Pharmaceuticals disclosed that accounting treatment of Milestone Warrants linked to its June 2026 PIPE and note exchange had driven stockholders’ equity below Nasdaq’s continued and initial listing thresholds as of June 30, 2026. Th...
Adial Pharmaceuticals Grants Inducement Stock Options to New Hire
NeutralOn August 19, 2026, Adial Pharmaceuticals granted a stock option to purchase 307,814 shares of common stock to a new employee as a material inducement to join the company, with an exercise price of $5.76 per share and a ten-year term. The option, app...
Adial Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
NegativeOn August 18, 2026, Adial Pharmaceuticals received a notice from Nasdaq that it no longer meets the $2.5 million minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, and also fails to qualify under altern...
Adial Pharmaceuticals Plans Major Leadership and Board Transition
NegativeAs of August 10, 2026, Adial Pharmaceuticals announced that, contingent on stockholder approval of certain proposals at its 2026 annual meeting, President and CEO Cary Claiborne and CFO Vinay Shah are expected to be terminated and receive contractual...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026